The developer of a sensor designed to continuously monitor indoor spaces for pathogens that could cause pandemics has been given a €500,000 prize by Germany’s Merck KGaA i
Roche has made its case for BTK inhibitor fenebrutinib as a potential new oral therapy for multiple sclerosis, with a phase 2 readout that it says shows significant improv
Germany’s Merck KGaA said this morning that the FDA has placed a partial clinical hold on its multiple sclerosis drug candidate evobrutinib, vying to become a new oral the
Biogen's efforts to replenish its multiple sclerosis pipeline have suffered a setback, after the FDA placed a clinical hold on a drug candidate it licensed from China's InnoCare last year f
Germany's Merck KGaA has said it needs to double the productivity of its R&D operations, with the aim of launching a new product every 18 months on average, to boost its pharma business
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.